tbuckley/cabot-search huggingface dataset:
American Society of Clinical Oncology Obesity Initiative: Rationale, Progress, and Future Directions
Authors: Jennifer A. Ligibel, Dana Wollins
Journal: Journal of Clinical Oncology (2016)

Obesity is increasingly being linked to the risk of developing and dying from cancer. In recognition of the growing contribution of obesity to cancer risk and outcomes, ASCO made obesity and cancer one of its core initiatives in 2014. The goals of this initiative included raising awareness of the relationship between obesity and cancer, providing tools and resources to oncology providers and patients to help encourage conversations regarding weight management in cancer survivors, fostering a robust research agenda, and advocating for access to evidence-based weight management programs for cancer survivors. Efforts to date have included developing patient and provider toolkits focused on weight management and physical activity, publishing a policy statement outlining ASCO's initiatives in this area, and hosting a summit focused on obesity research in cancer populations. As ASCO has defined its priorities in the area of obesity and cancer, it has become increasingly clear that obesity is a problem that extends far beyond its impact on cancer risk and outcomes. Many groups, including those focused on heart disease, diabetes, and endocrinology, have been developing, testing, and implementing obesity prevention and treatment strategies for years. As ASCO moves forward with its obesity initiative, the next steps will focus on forging collaboration with groups working on obesity-related initiatives both within and outside of the field of cancer to learn from their efforts and to partner with them on efforts to increase the education of medical professionals; raising awareness in lay populations regarding the negative health consequences of obesity and effective strategies to foster weight loss; developing collaborative research initiatives; and working together to advocate for the societal changes that will be needed to combat the obesity epidemic in the United States and beyond.
Lymphocyte/Monocyte Ratio (LMR) at Diagnosis Is Predictive of Survival with Post Transplant Lymphoproliferative Disease (PTLD) after Renal Transplant: An Analysis of 96 Patients of a Brazilian Cohort
Authors: Guilherme Fleury Perini, Egyla M Cavalcanti, Joao Garibaldi Junior, Adriana M. Damasco Penna, Jose Osmar Medina Pestana, Jose Orlando Bordin, Jose Pedro Zampieri Filho, Otavio C. G. Baiocchi
Journal: Blood (2015)
Estimate of the total costs of allergic rhinitis in specialized care based on real‐world data: the <scp>FERIN</scp> Study
Authors: C. Colás, M. Brosa, E. Antón, J. Montoro, A. Navarro, M. T. Dordal, I. Dávila, B. Fernández‐Parra, M. D. P. Ibáñez, M. Lluch‐Bernal, V. Matheu, C. Rondón, M. C. Sánchez, A. Valero
Journal: Allergy (2016)

Despite the socioeconomic importance of allergic rhinitis (AR), very few prospective studies have been performed under conditions of clinical practice and with a sufficiently long observation period outside the clinical trial scenario. We prospectively estimated the direct and indirect costs of AR in patients attending specialized clinics in Spain.Patients were recruited at random from allergy outpatient clinics in 101 health centers throughout Spain over 12 months. We performed a multicenter, observational, prospective study under conditions of clinical practice. We analyzed direct costs from a funder perspective (healthcare costs) and from a societal perspective (healthcare and non-healthcare costs). Indirect costs (absenteeism and presenteeism [productivity lost in the workplace]) were also calculated. The cost of treating conjunctivitis was evaluated alongside that of AR.The total mean cost of AR per patient-year (n = 498) was €2326.70 (direct, €553.80; indirect, €1772.90). Direct costs were significantly higher in women (€600.34 vs €484.46, P = 0.02). Total costs for intermittent AR were significantly lower than for persistent AR (€1484.98 vs €2655.86, P < 0.001). Total indirect costs reached €1772.90 (presenteeism, €1682.71; absenteeism, €90.19). The direct costs of AR in patients with intermittent asthma (€507.35) were lower than in patients with mild-persistent asthma (€719.07) and moderate-persistent asthma (€798.71) (P = 0.006).The total cost of AR for society is considerable. Greater frequency of symptoms and more severe AR are associated with higher costs. Indirect costs are almost threefold direct costs, especially in presenteeism. A reduction in presenteeism would generate considerable savings for society.
Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG)
Authors: Efstathios Kastritis, Konstantinos Zervas, Argiris Symeonidis, Evangelos Terpos, Sossana Delimpassi, Nicolaos Anagnostopoulos, Evridiki Michali, Athanasios Zomas, Irini Katodritou, Dimitra Gika, Anastasia Pouli, Dimitrios Christoulas, Maria Roussou, Theofanis Economopoulos, Meletios A Dimopoulos
Journal: Blood (2008)
Recovery of Donor Peripheral Blood Platelet Count Following Platelet Apheresis.
Authors: Larry J. Dumont, L. Lassahn, Peter A. Tomasulo, Dennis Harpool, S. Pinkard, Neeta Rugg, Jose A. Cancelas, S. Landry, Daniel R. Ambruso, Chris Clementi, Robert Schuyler
Journal: Blood (2007)
Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).
Authors: Rosaria De Filippi, Stefania Crisci, Ferdinando Frigeri, Donatella Aldinucci, Domenico Galati, Rosa Calemma, Giulio Abagnale, Gaetana Capobianco, Manuela Arcamone, Raffaele Di Francia, Laura Mettivier, Mariangela Saggese, Gaetano Corazzelli, Antonio Pinto
Journal: Blood (2012)
Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival
Authors: Ramy A. Abdelrahman, Kebede Begna, Darci Zblewski, Aref Al-Kali, Mrinal M. Patnaik, William Hogan, Ryan A Knudson, Rhett P Ketterling, Curtis A. Hanson, Mark R. Litzow, Ayalew Tefferi, Animesh Pardanani
Journal: Blood (2013)
Intravenous Immunoglobulin Post Allogeneic Stem Cell Transplantation Is Associated with Lower Levels of CMV Reactivation
Authors: Costas K Yannakou, Aaron J Robinson, Sumita Ratnasingam, Andrew Boon Ming Lim, Yvonne Panek-Hudson, Maggie Chau, Jeffrey Szer, David Ritchie
Journal: Blood (2014)
Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
Authors: Catarina Oliveira, Carole Fournier, Véronique Descamps, Virginie Morel, Corey A. Scipione, Rocco Romagnuolo, Marlys L. Koschinsky, Agnès Boullier, Paulo Marcelo, Jean‐Marc Domon, Etienne Brochot, Gilles Duverlie, Catherine Francois, Sandrine Castelain, Francois Helle
Journal: Hepatology (2017)

The development of different cell culture models has greatly contributed to increased understanding of the hepatitis C virus (HCV) life cycle. However, it is still challenging to grow HCV clinical isolates in cell culture. If overcome, this would open new perspectives to study HCV biology, including drug‐resistant variants emerging with new antiviral therapies. In this study we hypothesized that this hurdle could be due to the presence of inhibitory factors in patient serum. Combining polyethylene glycol precipitation, iodixanol gradient, and size‐exclusion chromatography, we obtained from HCV‐seronegative sera a purified fraction enriched in inhibitory factors. Mass spectrometric analysis identified apolipoprotein(a) (apo[a]) as a potential inhibitor of HCV entry. Apo(a) consists of 10 kringle IV domains (KIVs), one kringle V domain, and an inactive protease domain. The 10 KIVs are present in a single copy with the exception of KIV type 2 (KIV 2 ), which is encoded in a variable number of tandemly repeated copies, giving rise to numerous apo(a) size isoforms. In addition, apo(a) covalently links to the apolipoprotein B component of a low‐density lipoprotein through a disulfide bridge to form lipoprotein(a). Using a recombinant virus derived from the JFH1 strain, we confirmed that plasma‐derived and recombinant lipoprotein(a) as well as purified recombinant apo(a) variants were able to specifically inhibit HCV by interacting with infectious particles. Our results also suggest that small isoforms are less inhibitory than the large ones. Finally, we observed that the lipoprotein moiety of HCV lipoviroparticles was essential for inhibition, whereas functional lysine‐binding sites in KIV 7 , KIV 8 , and KIV 10 were not required. Conclusions : Our results identify apo(a) as an additional component of the lipid metabolism modulating HCV infection. (H epatology 2017;65:1851‐1864)
OP0281 Survival of Biopsy-Proven Giant Cell Arteritis in Italy during A 26-Year Period: Correlation with Histological Pattern
Authors: P. Macchioni, L. Boiardi, M. Catanoso, F. Muratore, A. Cavazza, P. Mancuso, G. Restuccia, C. Salvarani
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> No study have evaluated if there is a correlation between histological pattern of temporal artery biopsy and survival in patients with biopsy-proven giant cell arteritis (GCA). <h3>Objectives</h3> To investigate the relationship between histological pattern of temporal artery biopsy and survival in patients with biopsy-proven GCA in a defined area of Northern Italy. <h3>Methods</h3> All patients with incident temporal artery biopsy-positive GCA diagnosed between 1986 and 2012 living in the Reggio Emilia area were identified using pathology register and by reviewing all histopathological specimens. Patients were followed from the time of diagnosis until either their death or until December 31st, 2013. On the basis of the localization of the inflammation, positive TABs were classified into 4 categories: transmural inflammation (TMI), (229 cases, 81.8% of the positive biopsies); inflammation limited to adventitia (ILA), (14 cases, 5% of the positive biopsies); vasa vasorum vasculitis (VVV), (13 cases, 4.6% of the positive biopsies); and small vessel vasculitis (SVV), (24 cases, 8.6% of the positive biopsies). A semiquantitative 4 grade scale was used to describe the severity of mural inflammation (no mural inflammation, 81 cases, 28.9%, mild mural inflammation, 43 cases, 15.4%, moderate mural inflammation, 75 cases, 26.8%, severe mural inflammation, 81 cases, 28.9%). For each case, we identified one control from the same geographic area matched for age and gender. Mortality rates and specific causes of death were reported and compared between cases and controls and between cases with different histological pattern. TAB histological pattern and severity of mural inflammation entered in a Cox proportional regression analysis along with demographical, clinical and laboratory data at disease onset. <h3>Results</h3> There were 280 incident cases of biopsy-proven GCA (205 women, mean age at disease onset 74.3 + 7.5 y, mean duration of follow-up 95 + 58 months) during the 26-year study period with complete clinical, laboratory and survival data. During the follow- up period 159 (56.8%) patients died (mean survival time from disease onset 101 + 60 months). Patients with histological pattern ILA and VVV had reduced hazard ratio mortality as compared to TMI type (0.38 and 0.12 respectively). Survival of patients with different histological TAB pattern of GCA was not different from controls. The most frequent causes of death were cardiovascular diseases, cancer, and respiratory diseases. No significant differences in causes of death were observed comparing the 4 pattern of histological TAB involvement. <h3>Conclusions</h3> The histologic spectrum of inflammatory lesions in TAB positive GCA have correlation with survival. <h3>Disclosure of Interest</h3> None declared
Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-κB-mediated epithelial-mesenchymal transition
Authors: Weiping Zhu, Yiming Zhao, Jiamin Zhou, Xin Wang, Qi Pan, Ning Zhang, Longrong Wang, Miao Wang, Dihua Zhan, Zeyang Liu, Xigan He, Dening Ma, Shuang Liu, Lu Wang
Journal: Journal of Hematology & Oncology (2016)

Monoacylglycerol lipase (MAGL), a critical lipolytic enzyme, has emerged as a key regulator of tumor progression, yet its biological function and clinical significance in hepatocellular carcinoma (HCC) is still unknown. In this study, we used a tissue microarray containing samples from 170 HCC patients to evaluate the expression of MAGL and its correlation with other clinicopathologic characteristics. In addition, we investigated the regulating effects of MAGL on various HCC lines. Finally, we identified the NF-κB signaling pathway participated in MAGL-mediated epithelial-mesenchymal transition (EMT) using HCC cell lines with different metastatic potentials. The expression of MAGL was significantly higher in HCC tumors than in matched peritumor tissues. Specifically, high MAGL expression was found in tumors with larger tumor size, microvascular invasion, poor differentiation, or advanced TNM stage. In addition, the clinical prognosis for the MAGLhigh group was markedly poorer than that for the MAGLlow group in the 1-, 3-, and 5-year overall survival times and recurrence rates of HCC patients. MAGL expression was an independent prognostic factor for both survival and recurrence after curative resection. Furthermore, the upregulation of MAGL in HCC cells promoted cell growth and invasiveness abilities, and accompanied by EMT. In contrast, downregulation of MAGL obviously inhibited these characteristics. Moreover, further investigations verified that MAGL facilitates HCC progression via NF-κB-mediated EMT process. Our findings demonstrate MAGL could promote HCC progression by the induction of EMT and suggest a potential therapeutic target, as well as a biomarker for prognosis, in patients with HCC.
Pre-Load–Induced Changes in Forward LV Stroke and Functional Mitral Regurgitation
Authors: Yukio Abe, Kanako Akamatsu, Atsuko Furukawa, Kazato Ito, Yoshiki Matsumura, Kazuo Haze, Takahiko Naruko, Minoru Yoshiyama, Junichi Yoshikawa
Journal: JACC. Cardiovascular imaging (2016)
Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association
Authors: Robert Ross, Steven N. Blair, Ross Arena, Timothy S. Church, Jean-Pierre Després, Barry A. Franklin, William L. Haskell, Leonard A. Kaminsky, Benjamin D. Levine, Carl J. Lavie, Jonathan Myers, Josef Niebauer, Robert Sallis, Susumu S. Sawada, Xuemei Sui, Ulrik Wisløff
Journal: Circulation (2016)

Mounting evidence has firmly established that low levels of cardiorespiratory fitness (CRF) are associated with a high risk of cardiovascular disease, all-cause mortality, and mortality rates attributable to various cancers. A growing body of epidemiological and clinical evidence demonstrates not only that CRF is a potentially stronger predictor of mortality than established risk factors such as smoking, hypertension, high cholesterol, and type 2 diabetes mellitus, but that the addition of CRF to traditional risk factors significantly improves the reclassification of risk for adverse outcomes. The purpose of this statement is to review current knowledge related to the association between CRF and health outcomes, increase awareness of the added value of CRF to improve risk prediction, and suggest future directions in research. Although the statement is not intended to be a comprehensive review, critical references that address important advances in the field are highlighted. The underlying premise of this statement is that the addition of CRF for risk classification presents health professionals with unique opportunities to improve patient management and to encourage lifestyle-based strategies designed to reduce cardiovascular risk. These opportunities must be realized to optimize the prevention and treatment of cardiovascular disease and hence meet the American Heart Association’s 2020 goals.
AB0544 Serum Beta 2-Microglobulin Levels in behÇet's Disease
Authors: I.A. Choi, S.J. Lee, E.Y. Lee, E.B. Lee, Y.W. Song
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Behçet9s disease (BD) is a systemic vasculitis characterized by oral ulcer, genital ulcer, skin lesion and uveitis. Because there is no reliable biomarker, the evaluation of BD disease activity is dependent on the extent of clinical manifestation and usually assessed by questionnaires, such as Behcet9s Disease Activity Score (BSAS) or Behcet9s Disease Current Activity Form (BDCAF). <h3>Objectives</h3> This study was performed to investigate the association of serum beta 2-microglobulin level and clinical manifestation or disease activity in BD. <h3>Methods</h3> The study population consisted of 63 patients with BD and 21 healthy controls. Patients with BD were assessed by disease duration, currently involved organ, BSAS, BDCAF, ESR and CRP. <h3>Results</h3> Serum beta 2-microglobulin levels of patients with BD were found to be significantly higher than those in the healthy controls (median 1.67 mg/L and 1.44 mg/L, p=0.003). In further analysis in BD patients, it was significantly correlated with ESR (rho =0.289, p=0.025) and CRP (rho =0.364, p=0.004) but not correlated with BD activity represented by BSAS (rho = -0.039, p=0.761) and BDCAF (rho =0.011, p=0.929). Serum beta 2-microglobulin levels were significantly increased with age (rho =0.459, p&lt;0.001) but did not have correlation with BD duration (rho =0.161, p=0.212). There was no difference in the serum beta 2-microglobulin levels according to the presence of oral ulcer, genital ulcer, skin lesion, uveitis and arthritis. <h3>Conclusions</h3> Serum beta 2-microglobulin was elevated in patients with BD and correlated with ESR and CRP, but was not correlated with BD clinical manifestation or disease activity. <h3>Disclosure of Interest</h3> None declared
Nck Beta Adapter Protein Coordinates Bcr-Abl/Sam68 Intermolecular Interaction.
Authors: Enrico Bracco, Erika Deklic, Valentina Rosso, Stefano Mussino, Francesca Arruga, Sonia Carturan, Francesca Messa, Ilaria Defilippi, Cristina Panuzzo, Paolo Nicoli, Emanuela Messa, Antonia Rotolo, Roberto Pedrola, Alessandro Morotti, Alessandra Balbo, Ilaria Iacobucci, Giovanni Martinelli, Daniela Cilloni, Giuseppe Saglio
Journal: Blood (2008)
P0700 : Immunological rather than virological response to haart is associated with improved anti-HCV NK cell activity in HIV patients
Authors: A. Glässner, B. Krämer, F. Wolter, P. Kokordelis, F. Goeser, D. Kaczmarek, C. Boesecke, C. Schwarze-Zander, C.P. Strassburg, U. Spengler, J.K. Rockstroh, J. Nattermann
Journal: Journal of Hepatology (2015)
IL-2 Induces Selective Activation of Helios-Positive Regulatory T Cells and CD56bright NK Cells in Vitro and in Patients with Chronic Gvhd Receiving Low-Dose IL-2 Therapy
Authors: Masahiro Hirakawa, Tiago R Matos, John Koreth, Edouard Forcade, Jennifer Whangbo, Kazuyuki Murase, Hongye Liu, Sarah Nikiforow, Vincent T Ho, Corey S Cutler, Philippe Armand, Edwin P. Alyea, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz
Journal: Blood (2015)
SP0049 Nanoparticles and The Immune System
Authors: C. Strehl
Journal: Annals of the Rheumatic Diseases (2016)

An individually tailored diagnosis and therapy (theragnostic) could be beneficial in chronic, systemic, inflammatory autoimmune diseases like rheumatoid arthritis. The destructive nature of the disease, resulting in irreversible damages of cartilage and bone, demonstrates the urgent need for a very early diagnosis. Promising candidates for such a tool are represented by nanoparticles which have been intensively investigated over the last 20 years for various <i>in vitro</i> and <i>in vivo</i> biomedical applications. For example, nanoparticles are already in use as contrast enhancer for magnetic resonance imaging due to their favorable physicochemical properties and their biocompatibility. Further developments like surface modifications are ongoing. In order to permit the medical application of nanoparticles safety aspects need consideration. The collaborative project NanoDiaRA was funded by the European Union and focused on the “Development of novel nanotechnology based diagnostic systems for Rheumatoid Arthritis and Osteoarthritis”. Within the project, a novel generation of superparamagnetic iron oxide nanoparticles (SPION) was developed and their effect on human immune cell survival and activity was analyzed. The nanoparticles were modified stepwise until there was no negative influence of the improved type of SPION on human immune cells. Finally, the resulting generation of nanoparticles has been demonstrated to be suitable within the human system and, therefore, represent a promising tool for theragnostic in rheumatic diseases. <h3>Disclosure of Interest</h3> None declared
Effect of the Tyrosine Kinase Inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) On Blood Glucose Levels in Diabetic and Non-Diabetic Patients.
Authors: Nicole M. Agostino, Vernon M Chinchilli, Anita Koszyk-Szewczyk, Rebecca Gingrich, Jeff Sivik, Joseph Drabick
Journal: Blood (2009)
Comprehensive In Vitro and In Vivo Characterization of Loss and Gain-of-Function Von Willebrand Factor Collagen Binding Variants Using a Mouse Model System,
Authors: Yasuaki Shida, Christine Brown, Jeff Mewburn, Kate Sponagle, Ozge Danisment, Barbara Vidal, Carol A Heagadorn, David Lillicrap
Journal: Blood (2011)
Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study
Authors: Francesca Romana Mauro, Francesco Zaja, Stefano Molica, Marta Coscia, Anna Marina Liberati, Alfonso Piciocchi, Fiorella Ilariucci, Filomena Russo, Francesca Re, Alessandra Tedeschi, Anna Baraldi, Angelo Michele Carella, Alessandro Gozzetti, Giovanni Del Poeta, Agostino Cortelezzi, Roberta Battistini, Emilia Iannella, Antonietta Ferretti, Ilaria Del Giudice, Irene Della Starza, Sara Raponi, Maria Stefania De Propris, Caterina Ilari, Luciana Cafforio, Mauro Nanni, Paola Fazi, Marco Vignetti, Antonino Neri, Giorgina Specchia, Antonio Cuneo, Anna Guarini, Robin Foà
Journal: Blood (2015)